Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure

Miyashita, Yumi; Nishimura, Rimei; Nemoto, Masami; Matsudaira, Toru; Kurata, Hideaki; Yokota, Tamotsu; Yokota, Kuninobu; Tojo, Katsuyoshi; Utsunomiya, Kazunori; Tajima, Naoko
January 2008
Cardiovascular Diabetology;2008, Vol. 7, p1
Academic Journal
Background: The large clinical trials proved that Basal-Bolus (BB) insulin therapy was effective in the prevention of diabetic complications and their progression. However, BB therapy needs multiple insulin injections per a day. In this regard, a biphasic insulin analogue needs only twice-daily injections, and is able to correct postprandial hyperglycemia. Therefore it may achieve the blood glucose control as same as that of BB therapy and prevent the diabetic complications including macroangiopathy. Methods: In PROBE (Prospective, Randomized, Open, Blinded-Endpoint) design, forty-two type 2 diabetic patients (male: 73.8%, median(inter quartile range) age: 64.5(56.8~71.0)years) with secondary failure of sulfonylurea (SU) were randomly assigned to BB therapy with a thrice-daily insulin aspart and once-daily basal insulin (BB group) or to conventional therapy with a twice-daily biphasic insulin analogue (30 Mix group), and were followed up for 6 months to compare changes in HbA1c, daily glycemic profile, intima-media thickness (IMT) of carotid artery, adiponectin levels, amounts of insulin used, and QOL between the two groups. Results: After 6 months, HbA1c was significantly reduced in both groups compared to baseline (30 Mix; 9.3(8.1~11.3) ? 7.4(6.9~8.7)%, p < 0.01, vs BB;8.9(7.7~10.0) ? 6.9(6.2~7.3)%, p < 0.01), with no significant difference between the groups in percentage change in HbA1c (30 Mix; -14.7(-32.5~-7.5)% vs BB -17.8(-30.1~- 11.1)%, p = 0.32). There was a significant decrease in daily glycemic profile at all points except dinner time in both groups compared to baseline. There was a significant increase in the amount of insulin used in the 30 Mix group after treatment compared to baseline (30 Mix;0.30(0.17~0.44) ? 0.39(0.31~0.42) IU/kg, p = 0.01). There was no significant difference in IMT, BMI, QOL or adiponectin levels in either group compared to baseline. Conclusion: Both BB and 30 mix group produced comparable reductions in HbA1c in type 2 diabetic patients with secondary failure. There was no significant change in IMT as an indicator of early atherosclerotic changes between the two groups. The basal-bolus insulin therapy may not be necessarily needed if the type 2 diabetic patients have become secondary failure. Trial registration: Current Controlled Trials number, NCT00348231


Related Articles

  • Acupressure Therapy Inhibits the Development of Diabetic Complications in Chinese Patients with Type 2 Diabetes. Ke-Ke Jin; Lei Chen; Jing-Ye Pan; Jian-Min Li; Yang Wang; Fang-Yan Wang // Journal of Alternative & Complementary Medicine;Sep2009, Vol. 15 Issue 9, p1027 

    Objectives: The objectives of this study were to investigate the effects of acupressure therapy (AT) on the development and progression of diabetic complications in Chinese patients with type 2 diabetes (T2D). Design and methods: A total of 80 patients with T2D were recruited for a randomized...

  • A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Dailey, George // Formulary;Apr2005, Vol. 40 Issue 4, p114 

    Explores strategies for identifying patients with type 2 diabetes, who do not maintain glycemic control on oral agents, and for transitioning these patients to insulin. Data showing that patients are not reaching recommended glycemic goals and that they are delaying changes in therapy, which...

  • Serum glycoproteins in diabetic and non-diabetic patients with and without cataract. GUL, ANJUMAN; RAHMAN, M. ATAUR; AHMED, NESSAR // Optica Applicata;2008, Vol. 38 Issue 3, p531 

    This study describes the changes in serum glycoproteins from type 2 diabetic and non-diabetic patients with and without cataract. A total of 85 subjects were selected for the study and divided into four groups. The first group consisted of 21 healthy subjects, the second group consisted of 21...

  • Colesevelam hydrochloride: A novel agent in patients with type 2 diabetes. Sekhri, Kavita; Saha, Lekha // International Journal of Applied & Basic Medical Research;Jul2011, Vol. 1 Issue 2, p113 

    Hyperglycemia and hyperlipidemia are both risk factors for the development of various complications in patients with type 2 diabetes mellitus. Colesevelam hydrochloride is a novel agent that can improve both hypercholesterolemia and hyperglycemia in such patients. It is an orally administered...

  • A STUDY ON MALONDIALDEHYDE AS A MARKER OF LIPID PEROXIDATION IN MALE AND FEMALE PATIENTS WITH TYPE 2 DIABETES MELLITUS. Mallick, Ayaz K.; Maradi, Ravindra; Joshi, Vivek R.; Shorey, Gaurav; Ahsan, Marya // International Journal of Pharmaceutical Sciences Review & Resear;May/Jun2011, Vol. 8 Issue 2, p198 

    Diabetes mellitus (DM) is associated with hyperglycemia and oxidative stress. It is associated with various life threatening complications like nephropathy, retinopathy, atherosclerosis and coronary artery disease which adds up to the mortality among diabetics. These complications develop due to...

  • Glycemic Control and Pulmonary Function Tests in Type 2 Diabetes Mellitus Patients: Do They Correlate? Kumari, Kanya; Nataraj, S. M.; Devaraj, H. S. // Indian Journal of Public Health Research & Development;Apr-Jun2013, Vol. 4 Issue 2, p124 

    Diabetes is a multisystem disorder accompanied by widespread biochemical, morphological and functional abnormalities which may precipitate certain complications that affect the renal, cardiovascular, neural system, liver, skin and tissues like collagen and elastic fibers. This study was...

  • An Evaluation of New Agents in the Treatment of Type 2 Diabetes. Zimmerman, Bruce R.; Hagen, Michael D. // Journal of Family Practice;Nov1998 Supplement, Vol. 47 Issue 5, pS37 

    Several new medications for the treatment of hyperglycemia for patients with type 2 diabetes have been introduced in the past several years. Integration of these medications into practice has increased the complexity of therapeutic decisions. Appropriate use of these medications increases the...

  • Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study Ryuzo Kawamori; Koichi Node; Toshiaki Hanafusa; Yoshihito Atsumi; Yusuke Naito; Yoshitomo Oka // Cardiovascular Diabetology;2013, Vol. 12 Issue 1, p1 

    Background: The Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy (CREDIT) study is an international, multicenter, observational study designed to assess metabolic parameters and cardiovascular risk of patients with type 2 diabetes mellitus (T2DM) on insulin...

  • Morning Hyperglycemic Excursions. Monnier, Louis; Rabasa-Lhoret, Remy; Lapinski, Helene; Caubel, Cecile; Avignon, Antoine; Boniface, Helene; Colette, Claude // Diabetes Care;Apr2002, Vol. 25 Issue 4, p737 

    Presents a study that determined whether, over daytime, one or several hyperglycemic excursions exist that can be general failures in the glycemic control of patients with type 2 diabetes. Protocol of the study and analytical procedures; Comparison of plasma glucose and insulin concentrations...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics